%0 Generic
%A P., Balasubramanian
%A E., Chendamarai
%A P., Markose
%A L., Fletcher
%A S., Branford
%A B., George
%A V., Mathews
%A M., Chandy
%A A., Srivastava
%D 2012
%T Supplementary Material for: International Reporting Scale of BCR-ABL1 Fusion Transcript in Chronic Myeloid Leukemia: First Report from India
%U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_International_Reporting_Scale_of_i_BCR-ABL1_i_Fusion_Transcript_in_Chronic_Myeloid_Leukemia_First_Report_from_India/5123104
%R 10.6084/m9.figshare.5123104.v1
%2 https://karger.figshare.com/ndownloader/files/8708677
%2 https://karger.figshare.com/ndownloader/files/8708680
%K Chronic myeloid leukemia
%K Complete cytogenetic response
%K BCR-ABL1 transcripts
%K Major molecular response
%X Achieving a major molecular response (MMR) is an important predictor of progression-free survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate measurement of BCR-ABL1 transcripts normalized to a control gene, as well as defining a level (BCR-ABL1/control gene ratio) that will correlate with sustained clinical response. To make these measurements comparable between laboratories, an international scale (IS) is necessary. A BCR-ABL1/control gene ratio of 0.10% represents MMR in the IS. In collaboration with an international reference laboratory in Adelaide, S.A., Australia, we have established and validated a lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS. In this report, we explain the process and steps involved in obtaining a valid lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS.
%I Karger Publishers